Antisera, Latex Agglutination, Cryptococcus Neoformans
FDA product code GMD · Class II (moderate risk) · 21 CFR 866.3165 · Microbiology
10510(k) clearances
0PMA approvals
3recalls
Manufacturers
510(k) clearances
| 510(k) | Device | Applicant | Decision |
|---|---|---|---|
| K112422 | Crag Lateral Flow Assay (Lfa)GMD · Traditional | Immuno-Mycologics, Inc. | 03/28/2012SE |
| K102286 | Crag Lateral Flow Assay (Crag Lfa)GMD · Traditional | Immuno-Mycologics, Inc. | 07/20/2011SE |
| K930418 | Crypto-Lex SystemGMD · Traditional | Trinity Laboratories, Inc. | 02/17/1994SE |
| K933997 | Prospect Entamoeba Histolytica Microplate AssayGMD · Traditional | Alexon Biomedical, Inc. | 11/22/1993SE |
| K894845 | (Calas(Tm)) W/Add'L Reagent Calas(Tm) PronaseGMD · Traditional | Meridian Diagnostics, Inc. | 09/08/1989SE |
| K812188 | Cryptococcal Antigen Latex AgglutiGMD · Traditional | American Scientific Products | 08/31/1981SE |
| K810510 | Ya-Crypto Antibody Tube AgglutinationGMD · Traditional | Immuno-Mycologics, Inc. | 03/20/1981SE |
| K792693 | Cryptococcus Neoformans Antiserum, LatexGMD · Traditional | Meridian Diagnostics, Inc. | 01/21/1980SE |
| K791382 | Cryptococcal Antigen Latex AgglutinationGMD · Traditional | Immuno-Mycologics, Inc. | 08/16/1979SE |
| K780526 | Cryptococcal Antigen Latex Agg. SystemGMD · Traditional | I M, Inc. | 04/28/1978SE |
Recalls
| Recall | Product | Firm | Initiated |
|---|---|---|---|
| Z-0545-2022 Class II | CRYPTOCOCCAL ANTIGEN LATERAL FLOW ASSAY, IMMY, Lateral Flow Assay for the Detection of…The firm found immunoassay products used to detect cryptococcal antigen in serum and cerebrospinal fluid to… | Immuno-Mycologics, Inc | 01/03/2022Terminated |
| Z-2409-2018 Class II | Cryptococcal Antigen Lateral Flow Assay (CrAg LFA), Model # CR2003 Product Usage: The…Potential for LFA strips to improperly wick which may cause false negative cryptococcosis test results | Immuno-Mycologics, Inc | 03/30/2018Terminated |
| Z-1109-2017 Class II | Cryptococcal Antigen Lateral Flow Assay (CrAg LFA), Reference # CR2003The affected products have approximately a 91% specificity while the non-affected lots have approximately a… | Immuno-Mycologics, Inc | 12/27/2016Terminated |